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Peter Neglén, MD, PhD, T. Paul Tackett Jr, BS, and Seshadri Raju, MD, Flowood, Miss
Background: Arterial stenting across joints is not recommended because of increased risk of in-stent focal neointimal
hyperplasia and compression or fracture of the stent by joint motion with decreased long-term patency. The aim of this
study was to assess the risk of placing stents in the venous system across the inguinal ligament.
Materials and Methods: From 1997 to 2006, 177 limbs with chronic non-malignant obstructive lesions had stents placed
in the iliofemoral venous outflow across the inguinal ligament into the common femoral vein. Transfemoral venograms
and duplex ultrasound scans to assess cumulative patency rates, cumulative rates, site of in-stent restenosis (ISR), and
structural integrity of the stents were performed during follow-up. The results were compared to the findings in 316
limbs with stents terminating cephalad to the inguinal ligament.
Results: Overall cumulative secondary patency (CSP) rate at 54 months was greater in the limbs with cephalad than in
those caudad stent termination in relation to the inguinal ligament (95% and 86%, respectively; P  .0001). Although
CSP of limbs with non-thrombotic obstruction was 100% regardless of the site of stent termination, that of the limbs
stented for thrombotic obstruction was greater for stents terminating cephalad than for those caudad to the ligament
(90% and 84%, respectively; P  .0378). However, a comparison of CSP rates between limbs treated for thrombotic
occlusion and those with thrombotic non-occlusive obstruction at 32 months revealed no difference whether or not the
stent was placed across the inguinal ligament (occlusion 77% and 77%, P  .7540, non-occlusive obstruction 96% and
95%, P .7437). Severe ISR (>50%) were rare, 5%. The cumulative rate was, however, not significantly different in limbs
stented cephalad and caudad to the inguinal ligament (7% and 11%, respectively, P  .6393). Focal in-stent recurrent
stenosis at the site of the inguinal ligament occurred in only 7% of limbs (all <50%). None of the braided stainless steel
stents were compressed or fractured.
Conclusion: Contrary to arterial stenting, braided stainless stents can be safely placed in the venous system across the
inguinal crease with no risk of stent fractures, narrowing due to external compression, focal development of severe
in-stent restenosis, and no effect on long-term patency. The patency rate is not related to the length of stented area or the
placement of the stent across the inguinal ligament, but is dependent upon the etiology and whether the treated
postthrombotic obstruction is occlusive or non-occlusive. ( J Vasc Surg 2008;48:1255-61.)Venous stent placement in chronic femoro-ilio-caval
venous outflow obstruction has been shown to be a safe and
efficacious procedure.1-3 Long-term studies have shown a
high patency rate, low rate of in-stent restenosis, and lim-
ited need for re-interventions. The clinical outcome after
stenting is excellent with good symptom relief, low recur-
rence rate of healed venous ulcerations, and marked im-
provement of quality of life.4 Although technically a rather
simple procedure, attention to details is vital to achieve an
optimal result. Experience obtained from arterial stenting
may not necessarily be transferable to the venous system.
Stenting of arteries across moving joints, for example, is not
recommended because of damage to the stents and more
frequent development of intimal hyperplasia resulting in
poorer patency.5-7 There is a fear that this would also apply
to venous stenting. Several factors affecting stent-outcome
have been analyzed and reported in previous studies.4,8 In
the most recent study, proportional hazard expressed as
odds ratios and effect were calculated. Significant factors
associated with stent occlusion were younger age, chronic
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tension into the common femoral vein; sidedness, gender,
and thrombophilia were not associated with stent throm-
bosis or severe in-stent recurrent stenosis (50%). The
worse stent-related outcome observed when the venous
stenting was carried underneath the inguinal ligament into
the common femoral vein has lead many to conclude that
stents should not be placed at this site. The aim of this study
is to contest this conclusion by further assessment of the
patency, in-stent recurrent stenosis rate, and structural
integrity of venous stents placed across the inguinal liga-
ment.
MATERIALS AND METHODS
A review of a venous stent database of 1,085 limbs with
chronic non-malignant venous outflow obstruction col-
lected prospectively from 1997 to 2006 revealed 177 limbs
that had an iliofemoral stenting extending from the inferior
vena cava beneath the inguinal ligament into the common
femoral vein. The inguinal ligament cannot be visualized
radiologically. Its course is represented by a line between
the pectin ossis pubis close to the symphysis on the superior
pelvic ramus to the spina iliaca anterior superior of the iliac
bone on an anterior-posterior abdominal plain x-ray (Fig 1).
In practice, the stenting is directed by intravascular ultrasound
(IVUS) performed during the procedure. Stents extended
into the common femoral vein were reaching the inflow of
the profunda or circumflex veins and were, therefore,
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inguinal ligament. Stenting placed cephalad to the inguinal
ligament were placed above this line and usually terminated
in the middle or upper lower third of the external iliac vein
(Figs 2 and 3).
The intervention was performed for chronic non-
thrombotic iliac vein lesions (NIVL), so-called compres-
sion lesions (all non-occlusive) in 38 limbs, and for chronic
postthrombotic obstruction in 139 limbs (non-occlusive
obstruction in 78 limbs and occlusion in 61 limbs). The
obstructive lesion was considered thrombotic when the
patient had a known history of previous deep vein throm-
bosis (DVT) or when postthrombotic changes in the lower
extremity were found on venogram, duplex scan, or intra-
vascular ultrasound scan. Limbs treated by thrombolysis
prior to stenting were excluded. The female/male ratio was
2.8/1 and left/right limb involvement was 1.9/1. The
median age was 55 years (range, 22-91) (Table). The
diagnosis of obstruction, indications for iliofemoral stent-
ing, technical details of endovenous stenting, and periop-
erative anticoagulation treatment have been described pre-
viously.2,9-11 Braided stainless steel stents (Wallstents
Boston Scientific, Natick,Mass) weremost frequently used,
but in 18 limbs (10%) nitinol mesh stents were placed.
Limbs stented to a level cephalad to the inguinal liga-
Fig 1. Anterior-posterior view of a transfemoral antegrade
venogram including the left half of the pelvis. The line indicates the
course of the inguinal ligament (see text).ment were selected from the same database for comparison.Selection criteria were (1) termination of the iliac vein stent
system cephalad to the inguinal ligament as described
above and (2) first stent patency test performed by
venogram 4 months or later following the intervention
(stent may have been checked previously by duplex ultra-
sound scanning). These criteria were met by 316 limbs,
which reflected the patient characteristics and stent out-
come of the entire group of the 916 limbs in the database
with stenting terminating above the inguinal ligament.
All limbs were classified using the CEAP classification
Fig 2. Transfemoral venograms showing an obstruction of the
common and proximal external iliac vein (left) and the outflow
after placement of braided stainless steel stents (middle) (plain
x-ray; right). The stented area terminates well above the inguinal
ligament and the distal external iliac vein is normal.
Fig 3. Transfemoral venogram showing an extensive postthrom-
botic iliofemoral venous obstruction (left). The proximal nitinol
stent is placed, but there is a remaining stenosis of the common
femoral vein (middle). The stenting is extended underneath the
inguinal ligament covering the entire common femoral vein
(right). The upper and lower ends of the nitinol stent are shown by
radiopaque markers (line of dots).according to the Reporting Standards of International So-
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gery (ISCVS/SVS)12,13 based on duplex Doppler scan
study with standardized compression14,15 and transfemoral
antegrade and descending venography.16,17 The patients
were followed with transfemoral or ascending venography
and duplex Doppler ultrasound scan to assess patency,
degree of in-stent recurrent stenosis (ISR), and stent integ-
rity at 6 weeks, 4 and 9 months post-intervention, and then
annually. ISR was assessed as percentage diameter reduc-
tion of patent lumen of the stent on a face view venogram.
The degree of stenosis was measured using an electronic
caliper and calculated thusly: diameter of stent – diameter
of patent area/diameter of stent  100 (%). Cumulative
patency rates were calculated for limbs stented across the
inguinal ligament to compare groups of limbs with non-
thrombotic and thrombotic obstruction, and groups of
thrombotic limbs with varying degrees of obstruction
(non-occlusive and occlusive). In addition, cumulative pa-
tency rates were compared for groups of limbs with the
same etiology and degree of obstruction, but with stent
termination cephalad and caudad of the inguinal ligament
as determined by the extent of the obstruction. Secondary
patency rates are presented, since the main endpoint is
thrombotic occlusion of the stent in this study. An evalua-
tion and comparison of the cumulative rate of ISR was
possible in limbs which had transfemoral venograms during
follow-up.
Statistics. Categorical variables were analyzed by 2
test. Primary, assisted-primary (patency after preemptive
intervention) and secondary patency rates (patency after
intervention for occlusion) as defined by the reporting
standards of the ISCVS/SVS12 were calculated using sur-
vival analysis with the Kaplan-Meier method. Log-rank test
was used to compare cumulative curves. Commercially
available statistical programs (Graph Pad Prism for Win-
dows, version 3.0) were used for analysis. Results are re-
ported using P values. A P value of less than .05 was
Table. Characteristics of groups of limbs with stenting ter
CEAP classification is given (see text)
Caudad to inguinal ligamen
Number of limbs 177
Median age, years 55 (range, 22-91)
Female/male ratio 2.8/1
Left/right limb ratio 1.9/1
C2 8 (5%)
C3 75 (42%)
C4 42 (24%)
C5 8 (5%)
C6 44 (25%)
Eprimary 38 (21%)
Esecondary 139 (79%)
Adeep 65 (37%)
Asuperficial/deep 112 (63%)
Pobstruction 46 (26%)
Preflux/obstruction 131 (74%)considered significant.RESULTS
The characteristics of the groups of patients with stent-
ing reaching caudad and cephalad to the inguinal ligament
are shown in the Table. The age and gender distribution
were the same in both groups. The left leg dominated in
both groups, although it was more pronounced in the
comparison group. The distribution of the clinical severity
of the limbs in C-class 2-5 was not significantly different in
the two groups, but there were relatively more limbs with
leg ulcers (C-class 6) in those with stenting caudad to the
inguinal ligament. There was a significantly greater rate of
postthrombotic limbs, limbs with combined deep and su-
perficial disease, and limbs with combined reflux and ob-
struction among the patients with extensive stenting as
compared to those with stents terminating cephalad to the
inguinal ligament. These findings reflect that these limbs
had more complex, extensive, and severe infra-inguinal
venous disease. Transfemoral antegrade venograms of typ-
ical obstructions of varying extent are shown in Figs 2 and
3. When the obstruction involves the distal external iliae
vein (EIV) and proximal common femoral vein (CFV),
there is no alternative but to extend the stenting caudally. If
the full lesion is not treated the stent will most often
occlude.
A total of 163 limbs (92%) limbs with stenting caudad
to the inguinal ligament were followed for 19 months
(median; range, 1-95). Twenty-eight stent systems placed
in limbs treated for thrombotic obstruction occluded dur-
ing the observation period after 11 months (median; range,
1-66). Eleven limbs had successful thrombolysis and two
limbs failed removal of the thrombus; 15 limbs had no
intervention. Intervention of patent stents was performed
in 29 limbs. The majority (26 limbs, 90%) had balloon
venoplasty of in-stent restenosis, in three limbs combined
with distal stent extension, and in two limbs combined
ted cephalad and caudad to the inguinal ligament. Basic
Cephalad to inguinal ligament P value
316
53 (range, 15-81) .099
3.2/1 .653
3.0/1 .024
29 (9%) .088
149 (47%) .353
79 (25%) .837
17 (5%) .839
42 (13%) .002
191 (60%) .000
125 (40%)
158 (50%) .006
158 (50%)
136 (43%) .000
180 (57%)mina
tproximal and distal stent extensions. Three limbs had stent-
JOURNAL OF VASCULAR SURGERY
November 20081258 Neglén et aling alone; of these, one had distal stent extension, one had
proximal extension, and one had a combined procedure.
All 316 limbs with stents terminating above the ingui-
nal ligament were followed (a selection criterion for the
comparison group of limbs) for a median duration of 23
months (range, 2-103 months). Only five limbs had nitinol
mesh stents placed, while the remaining limbs were stented
with braided stainless steel stents. Nine of the latter stents
placed in limbs treated for thrombotic obstruction oc-
cluded during the observation period after 14 months
(median; range 2-66). Thrombolysis was successful in
three, failed in three, and was not attempted in three limbs.
Interventions for patent stents were performed in 68 limbs.
Additional stenting was performed more often in this
group of limbs (53 limbs, 78%). Most frequently, the stent
was extended caudally (38 limbs), in a few the direction was
in cephalad (5 limbs) or in both directions (7 limbs). Stents
bridging the gap between two stents were placed in 3 limbs.
Venoplasty of in-stent restenosis was combined with the
stent extension in 9 limbs, while it was the sole procedure in
15 limbs.
Cumulative secondary patency at 54 months was sig-
nificantly greater in the limbs with cephalad as compared to
caudad stent termination in relation to the inguinal liga-
ment, regardless of etiology of the treated obstruction (95%
and 86%, respectively; P  .0001) (Fig 4). None of the
stents placed in limbs with non-thrombotic obstruction
occluded during the observation period. Therefore, sec-
ondary patency in this group of limbs was 100% regardless
of the site of stent termination. In contrast, when limbs
stented for thrombotic obstruction were analyzed the pa-
tency was greater for stents terminating cephalad rather
than caudad to the inguinal ligament (90% and 84%, re-
spectively; P .0378) (Fig 5). A comparison of cumulative
secondary patency rates at 32 months between limbs
treated for thrombotic occlusion (requiring a recanaliza-
tion procedure) and those with thrombotic non-occlusive
Fig 4. Secondary patency rates in all limbs with iliofemoral stent-
ing terminating cephalad and caudad to the inguinal ligament (ing
lig). The lower numbers represent total limbs at risk for each time
interval (SEM 10%).obstruction revealed no difference whether or not the stentwas placed across the inguinal ligament (non-occlusive
obstruction 96% and 95%, P  .7437, and occlusion 77%
and 77%, P  .7540, stent termination cephalad and
caudad to inguinal ligament, respectively) (Fig 6). On the
other hand, comparing the limbs treated for non-occlusive
obstruction and occlusion with stents placed cephalad and
caudad to the ligament showed significant differences (P
.0010 and P  .0188, respectively). It is evident that the
patency rate was not related to the length of stented area or
the placement of the stent across the inguinal ligament, but
dependent upon the etiology and whether or not the
treated postthrombotic obstruction was occlusive or non-
occlusive.
Further support for this conclusion was found by anal-
ysis of the limbs with stenting performed across the inguinal
ligament only. The cumulative primary, assisted primary,
Fig 5. Secondary patency rates in limbs treated for thrombotic
obstruction with iliofemoral stenting terminating cephalad and
caudad to the inguinal ligament (ing lig). The lower numbers
represent total limbs at risk for each time interval (SEM 10%).
Fig 6. Secondary patency rates of stents placed in thrombotic
limbs for non-occlusive obstruction and occlusion with stenting
terminating cephalad and caudad to the inguinal ligament (ing lig).
The lower numbers represent total limbs at risk for each time
interval ( SEM).and secondary patency rates for all these limbs at 42months
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ary patency rates after stratification into groups of limbs
with NIVL, non-occlusive thrombotic disease, and throm-
botic occlusion at 42 months show deterioration of the
patency rate with more severe disease (100%, 91%, and
77%, respectively) (Fig 7).
Transfemoral venogram was performed at least once
during the observation period in 351 limbs (median 8
months after stenting; range, 1-86), allowing assessment of
the rate of ISR (289 limbs and 62 limbs with stenting
terminating cephalad and caudal to the inguinal ligament,
respectively). Limbs with re-occlusion of the stent system
were excluded in this analysis. During the follow-up, 115
limbs (115/351, 33%) developed 20% ISR, but only a
few (19/351, 5%) had severe ISR (50%). The cumulative
rates of in-stent recurrent stenosis at 48months are given in
Figs 8 and 9. Some degree of ISR (20%) developed more
frequently in limbs stented across the inguinal ligament
than in those with stent termination above the ligament
(60% and 37%, respectively; P .0001). A similar result was
found when limbs with thrombotic obstruction were com-
pared with those with non-thrombotic obstructions (50%
and 34%, respectively; P  .0016). The cumulative rate of
severe ISR (50%) was, however, not significantly differ-
ently in limbs stented cephalad and caudad to the inguinal
ligament (7% and 11%, respectively, P  .6393). Contrar-
ily, the rate was lower in limbs stented for non-thrombotic
obstruction than for thrombotic obstructions (1% and 14%,
respectively; P  .0003). The development of severe in-
stent recurrent stenosis, like stent patency rates, appeared
to be more related to the treatment of thrombotic obstruc-
tions rather than to extension of the stenting across the
inguinal ligament.
Focal in-stent recurrent stenosis occurred at the site of
the inguinal ligament in 7% of limbs stented across the
ligament and were not severe (50%). ISR extended
Fig 7. Secondary patency rates in limbs stented across the ingui-
nal ligament for nonthrombotic obstruction, non-occlusive
thrombotic obstruction, and thrombotic occlusion. The lower
numbers represent total limbs at risk for each time interval (SEM
10%). NIVL, non-thrombotic iliac vein lesion.throughout the entire stent in half of the limbs (52%),which developed 20% stenosis. Focal stenosis was more
common in limbs with stenting across the inguinal liga-
ment than those with stenting terminating cephalad to the
inguinal ligament (68% and 39%, respectively; P  .005).
The most common site was the external iliac vein in the
former limbs (68%), while in the latter limbs it was the
common iliac vein (66%). Nevertheless, the overall rate of
severe ISR (50%) was so low that no site analysis for these
can be performed confidently.
None of the braided stainless steel stents were com-
pressed or fractured. One of the nitinol stents was crushed
at the inguinal ligament (1/18, 6%). This required treat-
ment by insertion and venoplasty of a braided stainless stent
Fig 8. Cumulative rate of in-stent recurrent stenosis (20% and
50%) in limbs with stenting terminating cephalad and caudad to
the inguinal ligament (ing lig). The lower numbers represent total
limbs at risk for each time interval (SEM 10%).
Fig 9. Cumulative rate of in-stent recurrent stenosis (20% and
50%) in limbs treated for non-thrombotic and thrombotic ob-
structions. The lower numbers represent total limbs at risk for each
time interval (SEM 10%). ISR, in-stent recurrent stenosis.placed inside the nitinol stent.
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Arterial stenting across joints is not recommended.
Motion of the joint has been shown to enhance formation
of focal intimal hyperplasia in the stent at the joint sites,
which may decrease the long-term patency.5 Stents may
also be compressed, kinked, penetrate the vessel wall, or
fracture by the joint motion, especially if they are not
self-expandable.7,18-19 There is a fear that similar events
would occur when stents are placed in the same position in
the venous system and, thus, negatively affect outcome.
Therefore, many interventionists have refrained from stent-
ing underneath the inguinal ligament from the iliac vein to
the common femoral vein, even in instances in which the
common femoral vein is obviously involved in the disease
process. It is vital to ensure a sufficient in- and outflow of
the stent for long-term patency by covering the entire
obstructive lesion with stent. The length of stenting is
determined by the extent of the lesion as determined by
IVUS rather than to avoid crossing the inguinal ligament.
This study shows that it is safe to extend stenting across the
inguinal ligament when the obstructive lesion involves the
common femoral vein. Failure to do so will, almost without
exception, result in early occlusion of the stent.
Themechanism behind venous recurrent in-stent reste-
nosis is not well known and probably is different from
formation of “neointimal hyperplasia” in arterial stents.
Occlusion of venous stents has never been shown conclu-
sively to occur by an evolving progression of in-stent reste-
nosis. It is more likely to be caused by a novel thrombotic
event with acute thrombosis of the stent.8 Significantly
increased odds ratios for factors possibly contributing to
stent occlusion in an unselected material, have shown these
factors to be treatment for occlusion (9.0) and stenting
across the inguinal ligament (odds ratio 3.8), but not
thrombophilia (1.2). However, stent occlusion occurred
only when stents had been placed in limbs with previous
thrombosis.4 The group of limbs with stenting across the
inguinal ligament in this study had higher prevalence of
previous thrombosis (79%) than those with stents terminat-
ing above the inguinal ligament (40%). In addition, occlu-
sions, which were stented, were only found in limbs with
previous thrombosis. These limbs also appear to have a
more extensive postthrombotic disease with involvement of
the femoro-popliteal and profunda veins. The infra-stent
postthrombotic disease may result in a poor venous outflow
of the limb, decreasing the flow into the stent, and contrib-
ute to thrombosis of the stent. Layering of thrombotic
material along the stent has been observed immediately
after stent placement in a few cases with poor inflow.
Whether or not there is a sufficient inflow to sustain stent
patency is not presently possible to determine. The rela-
tionship of decreased inflow and stent thrombosis was not
assessed in this paper.
Analysis was made to further elucidate the previously
reported risk factors since there is obviously an intimate
relationship between limbs treated for thrombotic occlu-
sion, stenting across the inguinal ligament, and stent pa-tency. Cumulative secondary patency analysis of all limbs in
this study, regardless of etiology, showed a significantly
lower patency rate in limbs with stenting caudad than
cephalad to the inguinal ligament. This observation seems
to support the notion that there is a risk of extending the
stent into the common femoral vein across the hip joint.
Even when stents placed in limbs with non-thrombotic
lesions which had 100% patency, were excluded, this de-
creased patency rate was observed. Further analysis of the
stented thrombotic limbs revealed, however, that the pa-
tency rate was dependent on whether or not the treated
thrombotic vein was occluded. The extent of stenting
appeared not to influence stent patency outcome in these
limbs. The patency rate was not related to the placement of
the stent across the inguinal ligament but was dependent
upon the etiology, and whether or not the treated post-
thrombotic obstruction was occlusive (requiring recanali-
zation) or non-occlusive, ie, degree, not extent, of the
postthrombotic obstruction. This observation was also sup-
ported by the fact that the secondary patency rate in limbs
stented across the inguinal ligament was progressively less
in limbs treated for non- thrombotic obstruction, non-
occlusive thrombotic obstruction, and thrombotic occlu-
sion (100%, 91%, and 77%, respectively).
Previously, a higher rate of severe in-stent recurrent
stenosis in iliofemoral venous stents has been associated
with the presence of thrombophilia, long stents, and stents
crossing the inguinal ligament.8 This may have been ex-
plained by an over-representation of limbs with thrombotic
obstruction in these groups, which probably resulted in a
more severe and extensive obstructive disease. Recently,
the odds ratio for possible factors contributing to the
development of severe ISR in an unselected material was
high for limbs with thrombotic obstruction (26.7), occlu-
sion (8.3), and stenting caudad to the inguinal ligament
(5.5), but not associated with thrombophilia (1.2).4 This
study showed a greater development of in-stent recurrent
stenosis (20%) in limbs with the stent terminating caudad
to the inguinal ligament rather than in those with throm-
botic obstruction. Although some degree of ISR was
present inmany cases, severe ISR (50%) was found in only
19 limbs (5%) during the observation period. The extent of
the stenting in relationship to the inguinal ligament had no
influence on the cumulative rate of severe ISR, which
appeared to be dependent mainly on whether or not a
thrombotic obstruction was stented. Focal stenosis at the
level of the inguinal ligament was rare (7%) and none of
these were severe. Significant in-stent restenosis occurred
rarely in venous stents and no increase of focal stenosis was
found at the site of stent crossing the inguinal ligament.
In this study, the stent structure was intact in all braided
stainless steel stents placed in the venous system, while one
nitinol mesh stent was compressed at the level of the
inguinal ligament. No stent fracture or vessel erosion oc-
curred in any case. Thus, the structural integrity of the
venous stent is maintained despite movement of the hip
joint.
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stents can be safely placed in the venous system across the
inguinal crease with no risk of stent fractures, narrowing
due to external compression, or focal development of se-
vere in-stent restenosis. Patency of these stents is not asso-
ciated with the sub-inguinal site of placement, but is related
to the etiology of the obstruction with secondary patency
depending on the presence and severity of postthrombotic
obstructions. It is vital to ensure adequate in- and outflow
of the stented vein by covering the entire iliofemoral ob-
structive lesion as outlined by IVUS, even though this may
entail crossing the hip joint. Failure to extend the stent
under these circumstances creates a higher risk of stent
occlusion than does the stent extension itself.
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